Allergy & Asthma Network Mothers of Asthmatics (AANMA)

Sequestration Impacts FDA’s Ability to Deliver New Innovations to Allergy & Asthma Patients

Published May - 30 - 2013 Print This Post

Federal government sequestration cuts have begun. Sequestration is the employment of automatic, across-the-board spending cuts in the face of annual budget deficits. As members of the Alliance for a Stronger FDA, we (AANMA) have concluded that the FDA’s public health responsibilities cannot be accomplished with its existing budget, particularly post-sequestration.

Impact To You:

  • Under sequestration, FDA is subject to an approximate 5% cut to all spending ($209 million).
  • Simply put, the sequestration cuts threaten to delay the development of new asthma and allergy therapies that would help patients.

  • In addition, for the first time the federal government is considering subjecting FDA user fees to the sequester, meaning that FDA will not be able to collect $83 million in user fees in FY13. This would certainly further slow the agency’s ability to build up key programs and advance asthma and allergy medical product review programs that it agreed to earlier. User fees will remain unavailable to FDA unless a legislative fix is enacted.

Act Now & Speak Your Mind:

You can help stop this assault on FDA allergy and asthma programs.  Please contact your member of Congress and urge your Senators and Representatives to: (1) stop the unprecedented sequestration cuts to FDA user fees and, (2) voice your concern over the $209 million in FDA sequester cuts that threaten to delay and development of new allergy and asthma therapies that would help the 50 million Americans who have been diagnosed with these diseases.